Outcome of combination chemotherapy in extensive stage small-cell lung cancer: Any treatment related progress?

Lung Cancer

Volumn 20, Issue 3, 1998, Pages 151-160

  Lassen, Ulrik N ^a   Hirsch, Fred R ^a   Østerlind, Kell ^b   Bergman, Bengt ^c   Dombernowsky, Per ^d  

^a FINSEN LABORATORY   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Extensive stage; Prognostic factors; SCLC; Stage migration; Survival

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; METHOTREXATE; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METASTASIS; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031820834     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00011-7     Document Type: Article

References (30)

1. Pignon JP, Arriagada R, Ihde DCet al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. New Engl J Med. 327:1992;1618-1624.
2. Girling DJ, Hopwood P, Lallemand Get al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer. 73:1996;406-413.
3. Souhami RL, Spiro SG, Rudd RMet al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 89:1997;577-580.
4. Girling DJ, Thatcher N, Clark PIet al. Comparison of oral etoposide and standard multidrug intravenous chemotherapy for small cell lung cancer: a stopped multicentre randomised trial. Lancet. 348:1996;563-566.
5. Grant SC, Gralla RJ, Kris MGet al. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: The case for studies in previously treated patients. J Clin Oncol. 10:1992;484-498.
6. Bork E, Ersbøll J, Dombernowsky Pet al. Teniposide and etoposide in previously untreated small cell lung cancer: A randomized study. J Clin Oncol. 9:1991;1627-1631.
7. Ettinger DS, Finkelstein DM, Abeloff MD Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 84:1992;1077-1084.
8. Sagman U, Feld R, DeBoer Get al. Small cell carcinoma of the lung - Derivation of a prognostic index (Abstr). Clin Invest. 27:1986;189.
9. Souhami RL, Bradbury I, Geddes DMet al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 45:1985;2878-2882.
10. Østerlind K, Hansen HH, Hansen Met al. Long-term disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants. J Clin Oncol. 4:1986;1307-1313.
11. Wolf M, Holle R, Hans Ket al. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival. Br J Cancer. 63:1991;986-992.
12. Lassen U, Østerlind K, Hansen Met al. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - An analysis of 1714 consecutive patients. J Clin Oncol. 13:1995;1215-1220.
13. Aisner J Extensive-disease small-cell lung cancer: The thrill of victory; The agony of defeat. J Clin Oncol. 14:1996;658-665.
14. Dearing MP, Steinberg SM, Phelps Ret al. Outcome of patients with small-cell lung cancer: Effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 8:1990;1042-1049.
15. Hansen HH, Dombernowsky P, Hansen M Chemotherapy of advanced small-cell anaplastic carcinoma: Superiority of four drug combination. Ann Intern Med. 89:1978;177-181.
16. Hansen HH, Dombernowsky P, Hirsch FR Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic cranial irradiation in patients receiving combination chemotherapy. Cancer. 46:1980;279-284.
17. Hansen M, Hansen HH, Dombernowsky P Long-term survival in small cell carcinoma of the lung. J Am Med Assoc. 244:1980;247-250.
18. Østerlind K, Sörenson S, Hansen HHet al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res. 43:1983;6085-6089.
19. Østerlind K, Hansen HH, Hansen HSet al. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer. 54:1986;7-17.
20. Hirsch FR, Hansen HH, Hansen Met al. The superiority of combination chemotherapy including etoposide based on in vivo small-cell lung cancer: A randomized trial of 288 consecutive patients. J Clin Oncol. 5:1987;585-591.
21. Pedersen AG, Østerlind K, Vindeløv LL Alternating or continuous chemotherapy of small cell lung cancer. A three armed randomized trial (Abstr). Proc Am Soc Clin Oncol. 6:1987;187.
22. Østerlind K, Hansen M, Hirsch FR Combination chemotherapy of limited small cell lung cancer. A controlled trial on 222 patients comparing two alternating regimens. Ann Oncol. 2:1991;41-46.
23. Lassen U, Kristjansen PEG, Østerlind Ket al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol. 7:1996;365-371.
24. Bleehen NM, Fayers PM, Girling DJet al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer. 59:1989;584-590.
25. Roth BJ, Johnson DH, Einhorn LHet al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regiments in extensive small-cell-lung cancer: a Phase II trial of the Southeastern Cancer Study Group. J Clin Oncol. 10:1992;282-291.
26. Giaccone G, Dalesio O, Mcvie JGet al. Maintenance chemotherapy in small cell lung cancer: Long-term results of a randomized trial. J Clin Oncol. 11:1993;1230-1240.
27. Souhami RL, Rudd R, Elvira MRDet al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign Trial. J Clin Oncol. 12:1994;1806-1813.
28. Levitan N, Byrne RE, Bromer RHet al. The value of bone scan and bone marrow biopsy staging small cell lung cancer. Cancer. 56:1985;652-654.
29. Hansen SW, Jensen F, Pedersen NTet al. Detection of liver metastases in small-cell lung cancer: A comparison of peritoneoscopy with liver biopsy and ultrasonography with fine-needle aspiration. J Clin Oncol. 5:1987;255-259.
30. Hirsch FR, Østerlind K, Jensen LIet al. The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer. Ann Oncol. 3:1992;469-474.